Skip to content
Subscriber Only

Biogen Shares Plunge After Alzheimer’s Drug Setback

  • Biotech giant halts late-stage trials as results disappoint
  • Failure marks another misstep in efforts to find treatment
Video player cover image
Bloomberg Opinion columnist Max Nise reports on Biogen on “Bloomberg Daybreak: Americas.” His views are his own.Source: Bloomberg
Updated on

To read more about the future of health care, subscribe here to get our Prognosis newsletter delivered to your inbox every Thursday.

Biogen Inc. plummeted after the biotechnology giant said that its experimental Alzheimer’s drug was unlikely to be effective and that it was halting its research, in another setback for drugmakers’ efforts to find a therapy for the neurodegenerative ailment.